Scarica l'app Stockscreener
2.69
3.86%
0.10
Pre-mercato:
2.74
0.05
+1.86%
Absci Corp Borsa (ABSI) Ultime notizie
Millennium Management LLC Sells 1,149,603 Shares of Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Co. (NASDAQ:ABSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Transcript : Absci Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Two Sigma Investments LP Raises Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Deutsche Bank AG Purchases 28,073 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
Absci (NASDAQ:ABSI) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Absci (NASDAQ:ABSI) Stock Rating Lowered by Wall Street Zen - Defense World
AbSci Corp (ABSI) Sees Borrow Rate Increase | ABSI Stock News - GuruFocus
Woodline Partners LP Decreases Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Northern Trust Corp Has $1.72 Million Stock Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Brokerages Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40 - MarketBeat
Wall Street Zen Upgrades Absci (NASDAQ:ABSI) to Hold - Defense World
Ameriprise Financial Inc. Sells 23,668 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
AbSci Corp (ABSI): Key Indicator Shows Noticeable Increase | ABSI Stock News - GuruFocus
Catherine Wood's Strategic Acquisition of Absci Corp Shares - GuruFocus
Schonfeld Strategic Advisors LLC Has $144,000 Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
Absci Sets Stage for Major AI Breakthroughs at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Needham & Company LLC Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Stifel Financial Corp - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Absci (NASDAQ:ABSI) - Defense World
Absci Corp’s Earnings Call: A Promising Outlook - TipRanks
Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript - Insider Monkey
Absci First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI Stock News - GuruFocus
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 | ABSI Stock News - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101 - GuruFocus
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI S - GuruFocus
Assessing Absci: Insights From 6 Financial Analysts - Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Corporation Advances Clinical Programs with Strong Q1 Results - TipRanks
Fred Alger Management LLC Reduces Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Reve - GuruFocus
Absci earnings beat by $0.01, revenue fell short of estimates - Investing.com
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings By Investing.com - Investing.com Nigeria
AbSci (ABSI) Anticipates Significant Post-Earnings Movement | AB - GuruFocus
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings - Investing.com
Absci Q1 2025 Earnings Call Transcript - MarketBeat
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiat - GuruFocus
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiatives | ABSI Stock News - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial - TipRanks
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease - marketscreener.com
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease - GlobeNewswire
Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential - Stock Titan
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Has $115,000 Stock Position in Absci Co. (NASDAQ:ABSI) - Defense World
Absci (ABSI) Projected to Post Quarterly Earnings on Tuesday - Defense World
Absci (ABSI) Expected to Announce Earnings on Tuesday - MarketBeat
Mariner LLC Purchases New Stake in Absci Co. (NASDAQ:ABSI) - Defense World
Raymond James Financial Inc. Purchases Shares of 193,926 Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Envestnet Asset Management Inc. - Defense World
Marshall Wace LLP Reduces Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
128,400 Shares in Absci Co. (NASDAQ:ABSI) Acquired by Jump Financial LLC - MarketBeat
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):